Quanterix LucentAD
Quanterix has launched its LucentAD test to aid in the evaluation of patients with cognitive symptoms consistent with early Alzheimer's disease. The test measures phosphorylated tau-181 in plasma, which has been positively correlated with the presences of amyloid pathology in the brain. Quanterix will offer the assay as a lab-developed test run by its CLIA laboratory.